Response to : 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang
| Errataetall: |
CommentOn: Ann Rheum Dis. 2021 Aug;80(8):1014-1021. - PMID 33827787 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 82(2023), 7 vom: 01. Juli, Seite e169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wei, James Cheng-Chung [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.06.2023 Date Revised 14.06.2023 published: Print-Electronic CommentOn: Ann Rheum Dis. 2021 Aug;80(8):1014-1021. - PMID 33827787 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2021-220788 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327196084 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327196084 | ||
| 003 | DE-627 | ||
| 005 | 20231225200236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2021-220788 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327196084 | ||
| 035 | |a (NLM)34172504 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wei, James Cheng-Chung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to |b 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.06.2023 | ||
| 500 | |a Date Revised 14.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ann Rheum Dis. 2021 Aug;80(8):1014-1021. - PMID 33827787 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a ankylosing | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a spondylitis | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a brodalumab |2 NLM | |
| 650 | 7 | |a 6ZA31Y954Z |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Kim, Tae-Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Kishimoto, Mitsumasa |e verfasserin |4 aut | |
| 700 | 1 | |a Ogusu, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Haeyoun |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Shigeto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 82(2023), 7 vom: 01. Juli, Seite e169 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2023 |g number:7 |g day:01 |g month:07 |g pages:e169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2021-220788 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2023 |e 7 |b 01 |c 07 |h e169 | ||